What is HC Wainwright’s Forecast for SABS Q2 Earnings?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Research analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of SAB Biotherapeutics in a research note issued on Tuesday, May 12th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.24) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($1.10) EPS, FY2027 earnings at ($0.54) EPS, FY2028 earnings at ($0.42) EPS, FY2029 earnings at ($0.42) EPS and FY2030 earnings at ($0.43) EPS.

Other equities research analysts have also recently issued research reports about the company. Chardan Capital increased their price target on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Zacks Research upgraded SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday. Wall Street Zen cut SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Weiss Ratings restated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. Finally, Rodman & Renshaw restated a “buy” rating and issued a $13.00 price target on shares of SAB Biotherapeutics in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, SAB Biotherapeutics has an average rating of “Moderate Buy” and a consensus target price of $11.00.

SAB Biotherapeutics Trading Up 9.4%

NASDAQ SABS opened at $3.96 on Thursday. SAB Biotherapeutics has a 12 month low of $1.60 and a 12 month high of $6.60. The stock has a 50 day moving average of $3.86 and a 200-day moving average of $3.82. The company has a current ratio of 9.46, a quick ratio of 9.46 and a debt-to-equity ratio of 0.02. The company has a market cap of $201.76 million, a PE ratio of -1.88 and a beta of 0.55.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.15).

Institutional Trading of SAB Biotherapeutics

Several large investors have recently bought and sold shares of the business. Monashee Investment Management LLC acquired a new stake in SAB Biotherapeutics in the first quarter valued at about $1,915,000. PNC Financial Services Group Inc. acquired a new stake in SAB Biotherapeutics in the first quarter valued at about $29,000. Kestra Advisory Services LLC boosted its stake in SAB Biotherapeutics by 434.6% in the first quarter. Kestra Advisory Services LLC now owns 61,741 shares of the company’s stock valued at $236,000 after buying an additional 50,191 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in SAB Biotherapeutics in the fourth quarter valued at about $3,004,000. Finally, Millennium Management LLC acquired a new stake in SAB Biotherapeutics in the fourth quarter valued at about $1,212,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics News Roundup

Here are the key news stories impacting SAB Biotherapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target on SAB Biotherapeutics to $10 and reiterated a Buy rating, signaling more than 150% upside from recent levels and helping support sentiment around the stock.
• Positive Sentiment: The firm also published long-term earnings estimates that, while still negative, suggest a gradual improvement in losses over time, which may reassure investors that the company’s financial trajectory is improving.
• Positive Sentiment: Zacks Research upgraded SAB Biotherapeutics from Strong Sell to Hold, adding another constructive signal for the shares.
• Neutral Sentiment: SAB Biotherapeutics reported Q1 2026 EPS of ($0.35), missing the consensus estimate of ($0.20). The earnings miss is a fundamental headwind, but it was partially offset by investor focus on the company’s pipeline progress. SAB Biotherapeutics Q1 2026 earnings call
• Neutral Sentiment: Management said the registrational SAFEGUARD trial for SAB-142 is advancing, with enrollment expected to finish by the end of 2026 and topline data anticipated in 2H 2027, which supports the long-term pipeline story. SAB BIO Q1 2026 financial results and business highlights

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.